Related Experiment Video
Updated: Oct 19, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Failure of Biologic Therapy in Psoriasis
Rocío Cardona1, Natalia M Pelet Del Toro1, Eduardo Michelen-Gómez1
1School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
Puerto Rico Health Sciences Journal
|September 20, 2021
Summary
Biologic therapy failure in psoriasis patients was common, with ineffectiveness being the primary reason for discontinuation. Insurance coverage also impacted the use of etanercept and ustekinumab.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Biologic therapies are effective treatments for moderate-to-severe psoriasis.
- Understanding biologic therapy failure is crucial for optimizing patient care.
Purpose of the Study:
- To determine the frequency of biologic therapy failure in psoriasis patients.
- To identify patient demographics and characteristics associated with biologic therapy failure.
- To analyze common reasons for discontinuing biologic treatments.
Main Methods:
- Retrospective review of medical records for psoriasis patients.
- Study period: January 1st, 2013, to May 1st, 2018.
- Inclusion criteria: Patients who failed at least one biologic therapy.
Main Results:
- Seventy-seven patients discontinued biologic therapy at least once.
- Common comorbidities included hypertension (58.4%), diabetes (37.7%), and psoriatic arthritis (23.4%).
- Most used biologics: Adalimumab (80.5%), Ustekinumab (70.1%), Etanercept (14.2%). Ustekinumab had the longest mean duration of use (17.0 months) before discontinuation.
Conclusions:
- Ineffectiveness was the main reason for discontinuing biologic therapy.
- Insurance coverage issues contributed to discontinuation of etanercept and ustekinumab.
- No significant associations found between discontinuation and age, gender, or comorbidities; larger studies are needed.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
01:29Inflammatory Bowel Disease IV: Pharmacological Management
242
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
242
01:28Drug Products: Biologics, Biosimilars and Interchangeables
25
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
25
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
287
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
287
01:26Psychosis: Goals of Pharmacotherapy
263
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
263
01:24T Cell Types and Functions
1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K